Table 1. Sensitivity of human cancer cell lines to IFN as measured by antiviral assay.
| Sensitive | Moderately Resistant | Completely Resistant |
| (IFNCPE50 a <10 U/ml) | (IFNCPE50 10–5000 U/ml) | (IFNCPE50>5000 U/ml) |
| HeLa | A375 (ED50: 1695 U/ml) | DU145 |
| SKBR3 | DLD-1 (ED50: 40 U/ml) | HCT116 |
| SKOV3 | HT29 (ED50: 51 U/ml) | LNCaP |
| HTB129 (ED50: 28 U/ml) | PA-1 | |
| HT1080 (ED50: 219U/ml) | ||
| MCF7 (ED50: 46 U/ml) | ||
| MDAH (Ed50: 114 U/ml) | ||
| MDA-MB468 (ED50: 27 U/ml) | ||
| SW48 (Ed50: 3587 U/ml) |
a
IFN concentration that elicits a 50% protection against VSV infection based on analysis of cytopathic effects (CPE).